Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19-Reference-Cited by-同舟云学术

Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19

Published:2022-06-09 Issue:23 Volume:386 Page:2188-2200
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Levin Myron J.¹,Ustianowski Andrew¹,De Wit Stéphane¹,Launay Odile¹,Avila Miles¹,Templeton Alison¹,Yuan Yuan¹,Seegobin Seth¹,Ellery Adam¹,Levinson Dennis J.¹,Ambery Philip¹,Arends Rosalinda H.¹,Beavon Rohini¹,Dey Kanika¹,Garbes Pedro¹,Kelly Elizabeth J.¹,Koh Gavin C.K.W.¹,Near Karen A.¹,Padilla Kelly W.¹,Psachoulia Konstantina¹,Sharbaugh Audrey¹,Streicher Katie¹,Pangalos Menelas N.¹,Esser Mark T.¹

Affiliation:

1. From the University of Colorado School of Medicine, Aurora (M.J.L.); North Manchester General Hospital, Manchester (A.U.), Biometrics (A.T., S.S.) and Clinical Development (R.B., G.C.K.W.K.), Vaccines and Immune Therapies, Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, and Mounts Bay Medical, Penzance (A.E.) — all in the United Kingdom; the Division of Infectious Diseases, Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels (S.D.W.); Université de...

Funder

U.S. Department of Health and Human Services

U.S. Department of Defense

AstraZeneca

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2116620

Reference25 articles.

1. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data